Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Risk-Based Inspections Might Actually Be Hurting Compliant Firms

Executive Summary

Industry exec asks FDA to help good manufacturers prove to other countries they continue to meet GMPs even if they are not inspected frequently.


Related Content

Review Times Remain A GDUFA II Topic
GDUFA II: Inspection Information Takes Center Stage
Cheap Drugs Create Quality Temptations, FDA Official Says
Cheap Drugs Create Quality Temptations, FDA Official Says
Generic Drug Review Costs Still Largely Non-Personnel Related
GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table
FDA Field Operations Would Endure Reductions Under Budget
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
API Firms Advised to Gear Up for Inspections Under GDUFA and FMD
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst